Clinical Trials Logo

BRAF V600K Mutation Present clinical trials

View clinical trials related to BRAF V600K Mutation Present.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03975231 Recruiting - Clinical trials for Thyroid Gland Anaplastic Carcinoma

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Start date: September 14, 2020
Phase: Phase 1
Study type: Interventional

This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.